2. Academic Validation
  3. The interaction of cinchonine and immunoglobulin G and the development of a nanocomplex with improved anti-breast cancer activity

The interaction of cinchonine and immunoglobulin G and the development of a nanocomplex with improved anti-breast cancer activity

  • Int J Biol Macromol. 2025 Jan:287:138152. doi: 10.1016/j.ijbiomac.2024.138152.
Chunyan Wang 1,  Qiaobei Li 1,  Yuxin Hou 2,  Minglu Sun 3,  Jun Sun 4,  Zhe Lou 5,  Yinyan Li 6
Affiliations

Affiliations

  • 1 Department of Ultrasonic Diagnosis, The First Hospital of China Medical University, Shenyang 110001, China.
  • 2 Department of Ultrasonic Diagnosis, The Benxi Hospital of China Medical University, Benxi 117000, China.
  • 3 Department of Ultrasonic Diagnosis, The Cancer Hospital of China Medical University, Shenyang 110044, China.
  • 4 Department of Intervention, the Fourth Hospital of China Medical University, Shenyang 110036, China.
  • 5 Department of Cardiovascular Ultrasonic Diagnosis, The First Hospital of China Medical University, Shenyang 110001, China. Electronic address: 20161054@cmu.edu.cn.
  • 6 Department of Ultrasonic Diagnosis, The First Hospital of China Medical University, Shenyang 110001, China. Electronic address: 19982100@cmu.edu.cn.
PMID: 39613056 DOI: 10.1016/j.ijbiomac.2024.138152
Abstract

In this study we evaluated the interaction of cinchonine (Cin) and immunoglobulin G (IgG). Then, Cin-IgG nanoparticles (NPs) were synthesized and characterized. Finally, the Anticancer effects of free Cin and Cin-IgG NPs on MCF-7 breast Cancer (BC) cells were evaluated. The results of spectroscopy measurements show that the IgG-Cin complex's quenching mechanism is static and the structure of IgG was partially changed following interaction with Cin. The prepared Cin-IgG NPs display a hydrodynamic size of 190 nm with a PDI of 0.269, a zeta potential of -38.05 mV, an EE% of 72.38 %, a LC% of 5.41 %, and a pH-sensitive drug release behavior. In the cellular assay, it was found that the calculated IC50 concentrations of Cin, IgG NPs, and Cin-IgG NPs are 66.4 ± 5.39, >100, and 29.2 ± ± 4.11 μM, respectively, in MCF-7 BC cells. Finally, Cin-IgG NPs induce a greater effect on the overexpression of the Bax/Bcl-2 ratio and downregulation of PI3K/p-AKT compared to the free drug. In conclusion, this study shows that Cin has the potential to bind IgG as a human plasma protein, and its complexation into a NP form with IgG can boost its anti-BC effects.

Keywords

Breast cancer; Cinchonine; Immunoglobulin G; Interaction.

Figures
Products